Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Tag: Phase III Trial
FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...
Dave Bloom
-
2022/12/26
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Biologic Showing Promise as Food Allergy Treatment in Ongoing Phase 3...
Dave Bloom
-
2022/11/14
Assessment for both single agent and add-on therapy.
Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...
News Wire ~ 3rd Party Press Release
-
2022/11/11
73.5% of patients treated met the primary outcome at 12 months compared with 6.3% of patients in the placebo arm.
Private Law Firm to Investigate Claims on Behalf of Investors in...
Dave Bloom
-
2022/09/23
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial
Dave Bloom
-
2022/09/22
Another delay for the long-awaited therapy.
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
News Wire ~ 3rd Party Press Release
-
2022/09/19
Infants and young children finally get relief from eczema’s terrible itch
DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...
Dave Bloom
-
2022/09/14
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
News Wire ~ 3rd Party Press Release
-
2022/07/15
Majority of patients achieved histological disease remission in 16 weeks.
DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...
News Wire ~ 3rd Party Press Release
-
2022/06/08
Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Oral Medication Shows Strong Promise for Moderate to Severe Eczema in...
Dave Bloom
-
2021/05/21
Upadacitinib yielded rapid and significant improvements in patients with moderate to severe atopic dermatitis in phase 3 trials.
1
2
3
Page 1 of 3